The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded.
Emraclidine, a schizophrenia program expected to compete with the newly-approved Cobenfy from Bristol Myers Squibb and Karuna, failed in two separate Phase 2 studies, AbbVie ...
↧